Trametinib, a MEK (mitogen-activated protein kinase kinase) inhibitor with therapeutic relevance for melanoma treatment, was compared to the DNA-damaging agents doxorubicin and mitoxantrone as a therapeutic option in late-stage advanced malignant melanoma. This evidence concerns the gene MAP2K7 and melanoma.